前立腺肥大症(BPH)治療薬の世界市場...市場調査レポートについてご紹介

【英文タイトル】Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: BPH diagnostics
• Overview

PART 06: Pipeline landscape

PART 07: Market landscape
• Market overview
• Five forces analysis

PART 08: Market segmentation by MOA
• Alpha-blockers
• 5-ARIs
• PDE-5 inhibitors
• Others

PART 09: Geographical segmentation
• BPH drugs market in Americas
• BPH drugs market in EMEA
• BPH drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Advancements in early-stage diagnosis through new diagnostic methods
• Growing demand for MRI and ultrasound-guided prostate biopsy procedures
• Growing focus toward new MOA

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Risk factors of prostate gland enlargement
Exhibit 02: Difference between prostate cancer and BPH
Exhibit 03: Pipeline analysis
Exhibit 04: Pipeline landscape
Exhibit 05: Global BPH drugs market snapshot
Exhibit 06: Global BPH drugs market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Market segmentation by MOA 2016
Exhibit 09: Global BPH alpha-blockers drugs market 2016-2021 ($ millions)
Exhibit 10: Global BPH 5-ARIs drugs market 2016-2021 ($ millions)
Exhibit 11: Global BPH PDE-5 inhibitors drugs market 2016-2021 ($ millions)
Exhibit 12: Segmentation of global BPH drugs market based on geography 2016 and 2021 (%)
Exhibit 13: Global BPH drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 14: Market scenario in Americas
Exhibit 15: BPH drugs market in Americas 2016-2021 ($ millions)
Exhibit 16: Market scenario in EMEA
Exhibit 17: BPH drugs market in EMEA 2016-2021 ($ millions)
Exhibit 18: Market scenario in APAC
Exhibit 19: BPH drugs market in APAC 2016-2021 ($ millions)
Exhibit 20: Percentage of potential population for BPH among people with 65+ years 2014 and 2050
Exhibit 21: Prominent side effects of BPH medication
Exhibit 22: Impact of patent loss on AVODART 2014-2015 (GBP millions)
Exhibit 23: New advancements in diagnosis of BPH
Exhibit 24: Competitive structure analysis of global BPH drugs market 2016
Exhibit 25: Competitive analysis of global BPH drugs market
Exhibit 26: Astellas Pharma: Strength assessment
Exhibit 27: Astellas Pharma: Strategy assessment
Exhibit 28: Astellas Pharma: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: GlaxoSmithKline: Strength assessment
Exhibit 34: GlaxoSmithKline: Strategy assessment
Exhibit 35: GlaxoSmithKline: Opportunity assessment
Exhibit 36: Sanofi: Key highlights
Exhibit 37: Sanofi: Strength assessment
Exhibit 38: Sanofi: Strategy assessment
Exhibit 39: Sanofi: Opportunity assessment


【レポート販売概要】

■ タイトル:前立腺肥大症(BPH)治療薬の世界市場
■ 英文:Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021
■ 発行日:2017年5月10日
■ 調査会社:Technavio
■ 商品コード:IRTNTR13127
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。